AAP
XERS icon

Arax Advisory Partners’s Xeris Biopharma Holdings XERS Stock Holding History

Arax Advisory Partners’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65.9K Buy
8,319
+6,302
+312% +$40.2K ﹤0.01% 3051
2026
Q1 		$11.9K Buy
2,017
+385
+24% +$2.55K ﹤0.01% 2349
2025
Q4 		$12.8K Sell
1,632
-14,227
-90% -$112K ﹤0.01% 2350
2025
Q3 		$129K Buy
+15,859
New +$105K ﹤0.01% 1441
2025
Q1 		– Sell
-1,632
Closed -$5.53K – 3082
2024
Q4 		$5.53K Hold
1,632
– – ﹤0.01% 1709
2024
Q3 		$4.65K Hold
1,632
– – ﹤0.01% 1744
2024
Q2 		$3.67K Buy
+1,632
New +$3.29K ﹤0.01% 1721

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Arax Advisory Partners's XERS Position: Q2 2026 in Review

Arax Advisory Partners increased its Xeris Biopharma Holdings (XERS) stake by 312% in Q2 2026, buying an estimated $40.2K and bringing the position to 8,319 shares worth $65.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3051.

Arax Advisory Partners first reported a position in XERS in Q2 2024 and has held it in 7 quarters since. The position peaked at $129K in Q3 2025. 240 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • Arax Advisory Partners held 8,319 shares of Xeris Biopharma Holdings worth $65.9K as of Q2 2026.
  • Arax Advisory Partners bought 6,302 Xeris Biopharma Holdings shares in Q2 2026, an estimated $40.2K.
  • Xeris Biopharma Holdings made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3051 holding.
  • Arax Advisory Partners first reported a position in Xeris Biopharma Holdings in Q2 2024 and has held it in 7 quarters since.
  • Arax Advisory Partners's Xeris Biopharma Holdings position peaked at $129K in Q3 2025.
  • 240 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.